MicroRNA-199a could target CD44, restore chemosensitivity to paclitaxel, cisplatin, and adriamycin, and reduce ABCG2 expression, a multidrug resistance gene in in vitro and in vivo ovarian cancer models (63). The gene discussed is CD44; the disease is ovarian cancer.